These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 27041395

  • 1. Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries.
    Hallersten A, Fürst W, Mezzasalma R.
    Regul Toxicol Pharmacol; 2016 Jun; 77():275-81. PubMed ID: 27041395
    [Abstract] [Full Text] [Related]

  • 2. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J.
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [Abstract] [Full Text] [Related]

  • 3. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
    Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, Popovian R, Uy J.
    Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S.
    PLoS One; 2017 Jan; 12(12):e0190147. PubMed ID: 29284064
    [Abstract] [Full Text] [Related]

  • 7. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
    Danese S, Fiorino G, Michetti P.
    J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I, Kaspar B, Sharma U.
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [Abstract] [Full Text] [Related]

  • 10. Global regulatory standards for the approval of biosimilars.
    Mounho B, Phillips A, Holcombe K, Grampp G, Lubiniecki T, Mollerup I, Jones C.
    Food Drug Law J; 2010 Feb; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [Abstract] [Full Text] [Related]

  • 11. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland.
    O'Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, Griffin BT.
    Regul Toxicol Pharmacol; 2017 Aug; 88():252-261. PubMed ID: 28666961
    [Abstract] [Full Text] [Related]

  • 12. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG.
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Biosimilars].
    Krämer I.
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [Abstract] [Full Text] [Related]

  • 15. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
    Danese S, Gomollon F, Governing Board and Operational Board of ECCO.
    J Crohns Colitis; 2013 Aug; 7(7):586-9. PubMed ID: 23623738
    [Abstract] [Full Text] [Related]

  • 16. Biosimilars: Rationale and current regulatory landscape.
    Olech E.
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [Abstract] [Full Text] [Related]

  • 17. [Biosimilar drugs in oncology].
    Levêque D.
    Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
    [Abstract] [Full Text] [Related]

  • 18. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.
    Teeple A, Ellis LA, Huff L, Reynolds C, Ginsburg S, Howard L, Walls D, Curtis JR.
    Curr Med Res Opin; 2019 Apr; 35(4):611-617. PubMed ID: 30712393
    [Abstract] [Full Text] [Related]

  • 19. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR.
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.